Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18484671rdf:typepubmed:Citationlld:pubmed
pubmed-article:18484671lifeskim:mentionsumls-concept:C0012634lld:lifeskim
pubmed-article:18484671lifeskim:mentionsumls-concept:C0150369lld:lifeskim
pubmed-article:18484671lifeskim:mentionsumls-concept:C0010346lld:lifeskim
pubmed-article:18484671lifeskim:mentionsumls-concept:C0015733lld:lifeskim
pubmed-article:18484671lifeskim:mentionsumls-concept:C0014245lld:lifeskim
pubmed-article:18484671lifeskim:mentionsumls-concept:C0022942lld:lifeskim
pubmed-article:18484671lifeskim:mentionsumls-concept:C0950624lld:lifeskim
pubmed-article:18484671lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:18484671lifeskim:mentionsumls-concept:C0281481lld:lifeskim
pubmed-article:18484671pubmed:issue10lld:pubmed
pubmed-article:18484671pubmed:dateCreated2008-9-17lld:pubmed
pubmed-article:18484671pubmed:abstractTextFecal calprotectin and lactoferrin are promising noninvasive biomarkers for intestinal inflammation. In Crohn's disease (CD), during anti-TNF-alpha (TNF-alpha) treatment, the clinical significance of these markers has, however, been insufficiently explored.lld:pubmed
pubmed-article:18484671pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18484671pubmed:languageenglld:pubmed
pubmed-article:18484671pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18484671pubmed:citationSubsetIMlld:pubmed
pubmed-article:18484671pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18484671pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18484671pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18484671pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18484671pubmed:statusMEDLINElld:pubmed
pubmed-article:18484671pubmed:monthOctlld:pubmed
pubmed-article:18484671pubmed:issn1536-4844lld:pubmed
pubmed-article:18484671pubmed:authorpubmed-author:SavilahtiErkk...lld:pubmed
pubmed-article:18484671pubmed:authorpubmed-author:FärkkiläMartt...lld:pubmed
pubmed-article:18484671pubmed:authorpubmed-author:KolhoKaija-Le...lld:pubmed
pubmed-article:18484671pubmed:authorpubmed-author:KärkkäinenPäi...lld:pubmed
pubmed-article:18484671pubmed:authorpubmed-author:NuutinenHannu...lld:pubmed
pubmed-article:18484671pubmed:authorpubmed-author:TurunenUllaUlld:pubmed
pubmed-article:18484671pubmed:authorpubmed-author:SipponenTaina...lld:pubmed
pubmed-article:18484671pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18484671pubmed:volume14lld:pubmed
pubmed-article:18484671pubmed:ownerNLMlld:pubmed
pubmed-article:18484671pubmed:authorsCompleteYlld:pubmed
pubmed-article:18484671pubmed:pagination1392-8lld:pubmed
pubmed-article:18484671pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:18484671pubmed:meshHeadingpubmed-meshheading:18484671...lld:pubmed
pubmed-article:18484671pubmed:meshHeadingpubmed-meshheading:18484671...lld:pubmed
pubmed-article:18484671pubmed:meshHeadingpubmed-meshheading:18484671...lld:pubmed
pubmed-article:18484671pubmed:meshHeadingpubmed-meshheading:18484671...lld:pubmed
pubmed-article:18484671pubmed:meshHeadingpubmed-meshheading:18484671...lld:pubmed
pubmed-article:18484671pubmed:meshHeadingpubmed-meshheading:18484671...lld:pubmed
pubmed-article:18484671pubmed:meshHeadingpubmed-meshheading:18484671...lld:pubmed
pubmed-article:18484671pubmed:meshHeadingpubmed-meshheading:18484671...lld:pubmed
pubmed-article:18484671pubmed:meshHeadingpubmed-meshheading:18484671...lld:pubmed
pubmed-article:18484671pubmed:meshHeadingpubmed-meshheading:18484671...lld:pubmed
pubmed-article:18484671pubmed:meshHeadingpubmed-meshheading:18484671...lld:pubmed
pubmed-article:18484671pubmed:meshHeadingpubmed-meshheading:18484671...lld:pubmed
pubmed-article:18484671pubmed:meshHeadingpubmed-meshheading:18484671...lld:pubmed
pubmed-article:18484671pubmed:meshHeadingpubmed-meshheading:18484671...lld:pubmed
pubmed-article:18484671pubmed:meshHeadingpubmed-meshheading:18484671...lld:pubmed
pubmed-article:18484671pubmed:year2008lld:pubmed
pubmed-article:18484671pubmed:articleTitleFecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease.lld:pubmed
pubmed-article:18484671pubmed:affiliationDepartment of Medicine, Division of Gastroenterology, Helsinki University Central Hospital, Helsinki, Finland. taina.sipponen@kolumbus.filld:pubmed
pubmed-article:18484671pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18484671pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18484671lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18484671lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18484671lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18484671lld:pubmed